Matched profiling reveals MYC represses miR-29, increasing CD40 signaling in transformed follicular lymphoma, implying poor prognosis.
Follicular lymphoma (FL) patients are at risk of disease transformation to aggressive high-grade lymphoma (tFL). While several genetic alterations have been implicated in tFL, the role of microenvironmental interactions and post-transcriptional regulation by non-coding RNAs remains poorly understood. We performed the first matched profiling of mRNAs and short non-coding RNAs (miRNAs) in paired FL and tFL samples ( n = 11 pairs). This revealed differential expression of 1,075 mRNAs and 19 miRNAs, including repression of miR-29 family in tFL ( miR-29a/b/c ). Further analysis uncovered that MYC directly transcriptionally represses miR-29 in tFL, resulting in the upregulation of its target TRAF4. TRAF4 upregulation contributes to CD40 signaling being strongly activated in tFL and supports malignant B-cell proliferation. Notably, this increased CD40 pathway activity in 90% of tFL and contrasted with the reduced T-cell numbers in tFL niches. Thus, the MYC- miR-29 -TRAF4 axis and increased CD40 signaling propensity may serve as tFL cells’ adaptation to reduced numbers of CD40L+ T-cells. Moreover, lower levels of all miR-29s(a/b/c) were associated with shorter overall survival (OS) and progression-free survival in FL ( n = 185), including in a multivariate analysis. Low miR-29c was also associated with shorter OS in a validation cohort ( n = 92) from the first-line R-CHOP therapy clinical trial (SWOG S0016, NCT00006721).
No takes yet. Share an insight, caveat, or question.
Filip et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: